ALK and non-small cell lung carcinoma: The PROFILE 1007 trial is the first phase III trial comparing crizotinib to standard second-line chemotherapy (docetaxel or pemetrexed), in patients with advanced ALK-rearranged NSCLC, progressing after a first-line platinum-based chemotherapy.